Procedural volume and outcomes for transcatheter aortic-valve replacement

Sreekanth Vemulapalli, John D. Carroll, Michael J. Mack, Zhuokai Li, David Dai, Andrzej S. Kosinski, Dharam J. Kumbhani, Carlos E. Ruiz, Vinod H. Thourani, George Hanzel, Thomas G. Gleason, Howard C. Herrmann, Ralph G. Brindis, Joseph E. Bavaria

Research output: Contribution to journalArticlepeer-review

72 Scopus citations

Abstract

BACKGROUND: During the introduction of transcatheter aortic-valve replacement (TAVR) in the United States, requirements regarding procedural volume were mandated by the Centers for Medicare and Medicaid Services as a condition of reimbursement. A better understanding of the relationship between hospital volume of TAVR procedures and patient outcomes could inform policy decisions. METHODS: We analyzed data from the Transcatheter Valve Therapy Registry regarding procedural volumes and outcomes from 2015 through 2017. The primary analyses examined the association between hospital procedural volume as a continuous variable and risk-adjusted mortality at 30 days after transfemoral TAVR. Secondary analysis included risk-adjusted mortality according to quartile of hospital procedural volume. A sensitivity analysis was performed after exclusion of the first 12 months of transfemoral TAVR procedures at each hospital. RESULTS: Of 113,662 TAVR procedures performed at 555 hospitals by 2960 operators, 96,256 (84.7%) involved a transfemoral approach. There was a significant inverse association between annualized volume of transfemoral TAVR procedures and mortality. Adjusted 30-day mortality was higher and more variable at hospitals in the lowest-volume quartile (3.19%; 95% confidence interval [CI], 2.78 to 3.67) than at hospitals in the highest-volume quartile (2.66%; 95% CI, 2.48 to 2.85) (odds ratio, 1.21; P=0.02). The difference in adjusted mortality between a mean annualized volume of 27 procedures in the lowest-volume quartile and 143 procedures in the highest-volume quartile was a relative reduction of 19.45% (95% CI, 8.63 to 30.26). After the exclusion of the first 12 months of TAVR procedures at each hospital, 30-day mortality remained higher in the lowest-volume quartile than in the highest-volume quartile (3.10% vs. 2.61%; odds ratio, 1.19; 95% CI, 1.01 to 1.40). CONCLUSIONS: An inverse volume-mortality association was observed for transfemoral TAVR procedures from 2015 through 2017. Mortality at 30 days was higher and more variable at hospitals with a low procedural volume than at hospitals with a high procedural volume.

Original languageEnglish (US)
Pages (from-to)2541-2550
Number of pages10
JournalNew England Journal of Medicine
Volume380
Issue number26
DOIs
StatePublished - Jun 27 2019

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Procedural volume and outcomes for transcatheter aortic-valve replacement'. Together they form a unique fingerprint.

Cite this